| Autor: |
Minutolo, Roberto, Liberti, Maria Elena, Provenzano, Michele, Garofalo, Carlo, Borrelli, Silvio, Iodice, Carmela, Nicola, Luca De |
| Předmět: |
|
| Zdroj: |
Nephrology Dialysis Transplantation; Dec2022, Vol. 37 Issue 12, p2591-2593, 3p |
| Abstrakt: |
Our results, consistently with this previous evidence, suggest that the improvement of cardiorenal prognosis shown by the DAPA-CKD trial may translate to real-world patients. Following the positive results of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial [[1]], dapagliflozin is currently prescribed in patients with chronic kidney disease (CKD), with and without diabetes, in different countries. These data show that, in Italy, almost 17% of the CKD patients followed in renal clinics are representative of the DAPA-CKD trial population. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
